The global Chlamydia Diagnostics market revenue is anticipated to reach a market worth of US$ 3.69 billion by 2033. The market’s expansion might be due to increased awareness of the need of STI testing.
The Chlamydia Diagnostics market in Europe is predicted to increase significantly in the next years, owing to a number of factors. One of the primary market factors is the rising frequency of chlamydia in the region. According to a European Centre for Disease Prevention and Control research, the number of reported chlamydia infections in Europe has consistently increased over the last decade, with over 410,000 cases reported in 2019. The region’s demand for Chlamydia Diagnostics is predicted to rise as the prevalence of chlamydia rises.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16838
Another important factor driving the growth of the Chlamydia Diagnostics market is the availability of improved diagnostic tests. Because of their excellent sensitivity and specificity, nucleic acid amplification tests (NAATs) are the most routinely used diagnostic tests for chlamydia.
Furthermore, because these tests can detect bacterial DNA in a patient’s urine, swab, or blood sample, they are a convenient and non-invasive option for patients. Rapid diagnostic technologies, such as the Alere i platform and the Roche Cobas Liat System, have also been created in recent years, allowing for chlamydia diagnosis to be made quickly and accurately.
Key Takeaways from the Market Study
- By test type, NAATs are anticipated to account for 49% of the Chlamydia Diagnostics market in 2023.
- From 2023 to 2033, the global Chlamydia Diagnostics market is predicted to increase at an 11% CAGR.
- In 2023, North America is anticipated to hold 48% of the Chlamydia Diagnostics market.
- In 2023, Europe’s Chlamydia Diagnostics market is estimated to account for 46% of the total.
“Many organizations and governments are taking steps to raise awareness about the risks of STIs and the importance of early diagnosis and treatment. This, in turn, is expected to drive the growth of the market.” states an FMI analyst
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16838
Competitive Landscape
Key players in the Chlamydia Diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA Becton, Dickinson and Company, Bio-Rad Laboratories, Pfizer, Inc., AstraZeneca and Teva Pharmaceuticals
- Abbott has Laboratories collaborated with BASHH to develop and distribute the BASHH Chlamydia Quality Assurance Scheme. This program aims to improve the quality of chlamydia testing in clinical laboratories by providing a framework for quality assurance and standardization.
- The Roche has developed Cobas 4800 CT/NG test is a nucleic acid amplification test (NAAT) that can detect the DNA of both Chlamydia trachomatis and Neisseria gonorrhoeae in various clinical samples, such as urine, swabs, and endocervical samples. The assay is highly sensitive and specific and has been widely adopted by clinical laboratories for chlamydia and gonorrhea testing.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Edward’s syndrome treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Test Type (Culture Tests, Nucleic Acid Amplification Tests (NAAT), Direct Fluorescent Antibody Tests, Serology Tests) End User (Hospitals, Clinics, Diagnostic Centres) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16838
Key Segments Profiled in the Chlamydia Diagnostics Industry Survey
Test Type:
- Culture Tests
- Nucleic Acid Amplification Tests (NAAT)
- Direct Fluorescent Antibody Tests
- Serology Tests
End User:
- Hospitals
- Clinics
- Diagnostic Centres
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
